Mr. Gabriel Fahel reports

HELUS PHARMA ANNOUNCES COMPLETION OF LEGAL NAME CHANGE

Helus Pharma Inc.'s legal name has been changed from Cybin Inc. to Helus Pharma Inc., effective Oct. 1, 2026. The name change was approved by shareholders at the company's annual and special meeting of shareholders held on Sept. 22, 2026. The name change follows the company's adoption of the business name Helus Pharma on Jan. 5, 2026, and reflects the company's anticipated transformation from a clinical-stage discovery and development company to a commercial-ready pharmaceutical company.

The company's common shares will continue to trade on the Nasdaq Global Market and Cboe Canada under the ticker symbol HELP. No action is required by existing shareholders, and outstanding share certificates and DRS statements remain valid. The new Cusip number assigned to the company's common shares is 423492107, and its new ISIN is CA4234921076.

The company will continue to file documents under its updated profile on SEDAR+ and with the U.S. Securities and Exchange Commission on EDGAR.

About Helus Pharma Inc.

Helus Pharma is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company's proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety and other mental health conditions.

Helus Pharma is working to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received breakthrough therapy designation from the U.S. Food and Drug Administration, and HLP004, also a proprietary NSA in phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.

The company operates in Canada, the United States, the United Kingdom and Ireland.

We seek Safe Harbor.